HELP PEOPLE WITH CANCER
LIVE LONGER AND BETTER
1
MORE3D Medicines, Inc. is a commercial-stage biopharmaceutical company with a mission to help people with cancer live longer and better. Envisioning a future when cancer is managed as a chronic disease, 3D Medicines focuses on the development of differentiated next-generation immuno-oncology drugs, helping cancer patients live with prolonged survival time and a better quality of life. 3D Medicines has established a pipeline with both next-generation biological macromolecule and chemotherapeutic small-molecule drugs, as well as a professional team capable of global development, registration and commercialization operation.
Candidate Molecule
Target/
Mechanism
Rights
Preclinical
IND
Phase I
Phase II
Phase Ⅲ
NDA
Partner
Candidate
Molecule
Target/
Mechanism
Rights
Preclinical
IND
Phase I
Phase Ⅱ
Phase Ⅲ
NDA
Partner
MSI-H/dMMR advanced cancer (mono, 2L+)
Advanced BTC (combo with chemo vs. chemo, 1L)
NSCLC (vs standard treatment)
NSCLC (combo with chidamide, 2L+)
UC (mono vs. BSC, 1L maintenance, MRCT)
G/GEJ advanced cancer (combo with chemo, 1L)
TMB-H advanced cancer (mono, 2L+)
EC (mono and combo with lenvatinib, 2L+)
NSCLC, HCC, RCC (combo with lenvatinib)
HCC, CRC, NSCLC (combo with BD0801)
Locally advanced or metastatic solid tumors
Multiple indications
"With the increasing incidence of cancer, cancer has become one of the major public health problems facing mankind; it not only poses a major threat to human health, but also causes a serious burden to economic and social development.
With commitment to the R&D and commercialization of a next-generation of innovative immuno-oncology drugs, 3D Medicines hopes to provide cancer patients across the globe with more effective, more accessible, and more convenient options of next-generation immuno-oncology drugs, thus helping them to live longer and better."
-- John Gong, M.D., Ph.D., Chairman and CEO of 3D Medicines Inc.
News
Beijing, China April 18, 2022 - 3D Medicines Inc. (3D Medicines) announces that the multi-center, open-label phase Ib/II clinical trial of Batiraxcept (3D229) in combination with envafolimab or lenvatinib in patients with advanced solid tumor was approved by China’s National Medical Products Administration (NMPA).
2022-04
18
News
Beijing,April 6,2022 - 3D Medicines Inc. (the “Company”), today announced that an IND application to initiate the first clinical trial in China for 3D189, also known as SELLAS’s galinpepimut-s (“GPS”), has been approved by China’s National Medical Products Administration (“NMPA”) to evaluate safety and immunogenicity of 3D189 in Chinese patients with hematological malignancies.
2022-04
06
News
Beijing China, March 15, 2022 - 3D Medicines, a commercial-stage, oncology-focused Bio-pharmaceutical company, and Merck, a global leading science and technology company, today announced a partnership on clinical research. Under the collaboration, a clinical trial is designed to evaluate the combination of envafolimab, the world’s first subcutaneously injected PD-L1 antibody drug, and Erbitux® (cetuximab), an epidermal growth factor receptor (EGFR) inhibitor in the treatment of patients with RAS/BRAF wild-type, non-MSI-H/pMMR metastatic colorectal cancer (mCRC) who previously failed the treatment with fluorouracil, oxaliplatin, irinotecan and bevacizumab
2022-03
14